LLY
Health CareBulls ⚔ Bears · how Reddit is debating it
Bull case
0 stances- Injectable GLP-1 product is considered superior to NVO's offering. ↗
- Passes the Value Score threshold of 2.0, highlighting a compelling mix of profitability and growth. ↗
- Included in the current portfolio, signaling confidence in its current valuation. ↗
- Selected by author's proprietary Value Score model (>2.0), indicating strong undervaluation relative to growth and margins. ↗
- Included in the author's core portfolio that has achieved a 65.8% YTD return. ↗
- Poised to capture the next leg of the GLP-1 trade with oral formulations like orforglipron. ↗
Bear case
0 stances- Novo's promising pipeline candidates like UBT251 could take meaningful market share and challenge Eli Lilly's current dominance in obesity treatments. ↗
- Novo's promising pipeline candidates, such as UBT251, are expected to capture meaningful market share and challenge Eli Lilly's current dominance in obesity treatments. ↗
- The post relies heavily on hype ('rocket fuel', 'ignite') rather than detailed financial valuation or risk analysis. ↗
- Market expectations may already be priced in given the anticipation mentioned ('bought a ton of their stock'). ↗
- Single-day price action is statistically insignificant and prone to noise rather than signaling a trend. ↗
- Resilience may reflect temporary capital rotation rather than sustainable long-term value appreciation. ↗
Credible voices
Catalysts · themes
Community split
Related narratives
High-quality DD posts
Novo Nordisk's recent price cuts will solidify its market dominance, deter competitors, and unlock massive growth in Europe and its pipeline.
Novo Nordisk's price cuts will deter competitors, while European expansion and a promising pipeline challenge Eli Lilly's dominance.
Author is furious about NVO's poor stock performance despite GLP-1 leadership, blaming terrible management or fraud.
The author jokingly values his side hustle using P/E ratios of TSLA, AVGO, LLY, and MA, sarcastically offering shares to Reddit users.
Author shares a value model based on growth, margins, and EV multiples, holding MU, NVDA, GOOGL, LLY, MSFT, META with 65.8% YTD returns.
Author shares a value model based on growth, margins, and EV multiple, holding MU, NVDA, GOOGL, LLY, MSFT, META with 65.8% YTD return.
Big pharma's patent cliff drives aggressive M&A, creating a floor for small-cap biotech, while GLP-1 oral versions offer new growth.
Bullish on LLY due to promising Phase 3 results for Retatrutide, claiming superiority over Novo's pipeline and expanded indications.
An 18yo seeks advice on an aggressive Roth IRA portfolio, questioning tech concentration and international exposure.
18yo asks for feedback on an aggressive Roth IRA portfolio heavily weighted towards US tech and large-cap ETFs.
User questions if LLY's resilience during a broad market sell-off indicates strong bullish momentum and a buy signal.

r/wallstreetbets
r/valueinvesting
r/investing
r/stocks
r/stockmarket